Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a targeted cancer drug deliver in the real world?

NCT ID NCT06846996

Disease control Sponsor: Daiichi Sankyo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This observational study is tracking 260 adults in China with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants are receiving trastuzumab deruxtecan (T-DXd) as part of their routine care, and researchers are collecting data on how long the treatment works before it stops being effective and what side effects occur. The goal is to see if the promising results from clinical trials hold up in everyday practice, especially for Chinese patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate that targets HER2-positive cancer cells
What this could lead to
If successful, this study could provide stronger evidence that T-DXd works well and is safe for Chinese patients with HER2-positive stomach cancer, potentially improving treatment guidelines and access.
What could go wrong
As an observational study, it does not compare T-DXd to other treatments, so results may be influenced by patient differences. Side effects, including serious ones, are still possible and will be monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants for this study include participants with HER2-positive local advanced or metastatic GC/GEJA.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants must meet all the following inclusion criteria to be eligible for the study: 1. Participants with pathologically diagnosed locally advanced unresectable or metastatic gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJA). 2. ≥18 years of age at the time of starting the first dose of T-DXd and signing informed consent form (ICF), capable of providing informed consent. 3. HER2-positive status (IHC 3+ or IHC 2+/ISH +). 4. Received prior anti-cancer treatment regimens according to National Medical Products Administration indication or clinical judgement of physician. 5. Decision to newly initiate T-DXd before study ICF signing. If the participants have started the first dose of T-DXd no longer than 21 days before enrollment, they could be enrolled if the signed and dated ICF could be obtained. Exclusion Criteria： Participants who meet any of the following criteria will be excluded from the study: 1. Pregnancy or breastfeeding. 2. Participants who at the time of data collection of the study are participating in or have participated in an interventional study that remains blinded. 3. Known hypersensitivity to either the drug substances or inactive ingredients in the drug product. 4. Judged by the investigator to be unfit to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-positive gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-positive gastric cancer HER2-positive gastroesophageal junction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    36 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    RECRUITING

    Guangzhou, 510095, China

  • Anhui Province Cancer Hoospital

    RECRUITING

    Hefei, 236000, China

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, 100142, China

  • Beijing Chaoyang Hospital, Capital Medical University

    RECRUITING

    Beijing, 100020, China

  • Beijing Friendship Hospital,Capital Medical University

    RECRUITING

    Beijing, 100032, China

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, 102206, China

  • Cancer Hospital of Shantou University Medical College

    RECRUITING

    Shantou, 515000, China

  • Changzhi People's Hospital

    RECRUITING

    Changzhi, 046000, China

  • China-Japan Friendship Hospital

    RECRUITING

    Beijing, 100029, China

  • Chinese Academy of Medical Sciences Cancer Hospital

    RECRUITING

    Beijing, 100021, China

  • Fudan University Affiliated Cancer Hospital

    RECRUITING

    Shanghai, 200032, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, 350000, China

  • Guangdong Hospital of Traditional Chinese Medicine

    RECRUITING

    Guangzhou, 510120, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, 510080, China

  • Hainan General Hospital

    RECRUITING

    Haikou, 570100, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, 450008, China

  • Huadong Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, 201104, China

  • Jiangmen Central Hospital

    RECRUITING

    Jiangmen, 529000, China

  • Jiangsu Cancer Hospital

    RECRUITING

    Nanjing, 210009, China

  • Liaoning Cancer Hospital

    WITHDRAWN

    Shenyang, 110000, China

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, 210000, China

  • Peking Union Medical College Hospital

    WITHDRAWN

    Beijing, 100032, China

  • Peking University First Hospital

    RECRUITING

    Beijing, 100034, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, 200025, China

  • Shanghai GoBroad Cancer Hospital

    RECRUITING

    Shanghai, 200003, China

  • Shanghai ninth People's Hospital,Shanghai Jiaotong University School of Medicine

    NOT_YET_RECRUITING

    Shanghai, 200011, China

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, 030000, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    WITHDRAWN

    Hangzhou, 310009, China

  • Taizhou Hospital of Zhejiang Province

    RECRUITING

    Taizhou, 317700, China

  • The Affiliated Hospital of Xi'an Jiaotong University

    RECRUITING

    Xi'an, 710061, China

  • The Affiliated Hospital of Xiamen University

    RECRUITING

    Xiamen, 361003, China

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, 221006, China

  • The First Affiliated Hospital of Zhengzhou University

    WITHDRAWN

    Zhengzhou, 450066, China

  • The First Affiliated Hospital, Sun Yat-sen University

    RECRUITING

    Guangzhou, 510080, China

  • The First Hospital of Jilin University

    NOT_YET_RECRUITING

    Changchun, 130031, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, 310009, China

  • The Second Hospital of Tianjin Medical University

    RECRUITING

    Tianjin, 300211, China

  • Tianjin Medical University Cancer Institute and Hospital

    RECRUITING

    Tianjin, 300000, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, 310005, China

  • Zhongshan Hospital

    RECRUITING

    Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.